Compare PAYO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | VERA |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | 2540 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 3.2B |
| IPO Year | N/A | 2021 |
| Metric | PAYO | VERA |
|---|---|---|
| Price | $4.94 | $34.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $7.69 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 3.6M | 945.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $10.28 | $472.48 |
| P/E Ratio | $30.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.08 | $18.76 |
| 52 Week High | $7.67 | $56.05 |
| Indicator | PAYO | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 40.91 |
| Support Level | $4.82 | $34.04 |
| Resistance Level | $5.31 | $42.77 |
| Average True Range (ATR) | 0.21 | 1.86 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 59.06 | 23.02 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.